INT101342

From wiki-pain
Revision as of 22:21, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 3.68
Pain Relevance 2.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2A6) endoplasmic reticulum (CYP2A6) enzyme binding (CYP2A6)
Anatomy Link Frequency
epithelial cells 1
CYP2A6 (Homo sapiens)
Pain Link Frequency Relevance Heat
Nicotine 370 99.36 Very High Very High Very High
Dextromethorphan 1 99.04 Very High Very High Very High
Paracetamol 8 91.04 High High
opiate 3 79.44 Quite High
antagonist 15 77.00 Quite High
Opioid 126 73.76 Quite High
addiction 140 73.64 Quite High
opioid receptor 9 72.32 Quite High
Analgesic 16 66.72 Quite High
Pain 22 62.64 Quite High
Disease Link Frequency Relevance Heat
Repression 1 100.00 Very High Very High Very High
Nicotine Addiction 756 98.32 Very High Very High Very High
Overdose 4 91.40 High High
Thalassemia 28 90.60 High High
Lung Cancer 6 88.96 High High
Exanthema 6 88.80 High High
Myelodysplastic Syndromes 19 85.28 High High
Renal Disease 4 84.88 Quite High
Constipation 50 78.24 Quite High
Cancer 16 76.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Selective inhibition of CYP3A4 and CYP1A2 did not reduce, whereas the inhibition of CYP2A6 and CYP2E1 significantly decreased NAPQI formation.
Negative_regulation (inhibition) of CYP2A6
1) Confidence 0.53 Published 2002 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 11866476 Disease Relevance 0.24 Pain Relevance 0.39
Renzapride did not inhibit the major CYP drug-metabolizing enzymes CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2E1 or CYP3A4 at concentrations consistent with use in a clinical setting.
Negative_regulation (inhibit) of CYP2A6
2) Confidence 0.49 Published 2008 Journal Drugs R D Section Body Doc Link 18095752 Disease Relevance 0 Pain Relevance 0
It is a weak inhibitor of CYP2C8, CYP2C19, and CYP2A6, and a mild-to-moderate inhibitor of CYP2C9 at therapeutic concentrations.34,35 Accordingly, fenofibric acid may have the potential to cause various pharmacokinetic drug interactions.
Negative_regulation (inhibitor) of CYP2A6
3) Confidence 0.45 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 0.16 Pain Relevance 0
This contrasts the finding of Crawford et al. (1998), who demonstrated repression of CYP2A6/7 in human bronchial epithelial cells of smokers.
Negative_regulation (repression) of CYP2A6 in epithelial cells associated with nicotine addiction and repression
4) Confidence 0.42 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.58 Pain Relevance 0
Although allele frequencies in African-Americans have not been reported, this group tends to have a generally decreased nicotine clearance, which may be due to decreased CYP2A6 activity [134].
Negative_regulation (decreased) of CYP2A6 associated with nicotine
5) Confidence 0.37 Published 2004 Journal Tob Induc Dis Section Body Doc Link PMC2669467 Disease Relevance 0.31 Pain Relevance 0.36
Although allele frequencies in African-Americans have not been reported, this group tends to have a generally decreased nicotine clearance, which may be due to decreased CYP2A6 activity [134].
Negative_regulation (decreased) of CYP2A6 associated with nicotine
6) Confidence 0.37 Published 2004 Journal Tob Induc Dis Section Body Doc Link PMC2671538 Disease Relevance 0.31 Pain Relevance 0.36
In vitro, it does not inhibit CYP1A2, CYP2A6, CYP2C9, CYP2C19, or CYP3A4.
Negative_regulation (inhibit) of CYP2A6
7) Confidence 0.36 Published 2010 Journal Core evidence Section Body Doc Link PMC2899781 Disease Relevance 0.67 Pain Relevance 0.59
However, if variant alleles do indeed affect metabolism and smoking behavior, then the efficacy of nicotine-replacement therapy can be greatly increased by identifying and using inhibitors of CYP2A6 [145-147].
Negative_regulation (inhibitors) of CYP2A6 associated with nicotine addiction and nicotine
8) Confidence 0.24 Published 2004 Journal Tob Induc Dis Section Body Doc Link PMC2671538 Disease Relevance 0.39 Pain Relevance 0.34
However, if variant alleles do indeed affect metabolism and smoking behavior, then the efficacy of nicotine-replacement therapy can be greatly increased by identifying and using inhibitors of CYP2A6 [145-147].
Negative_regulation (inhibitors) of CYP2A6 associated with nicotine addiction and nicotine
9) Confidence 0.24 Published 2004 Journal Tob Induc Dis Section Body Doc Link PMC2669467 Disease Relevance 0.39 Pain Relevance 0.34
Deferasirox also inhibits CYP1A2, CYP2A6, CYP2D6, and CYP2C19, however the clinical significance of this is unknown.
Negative_regulation (inhibits) of CYP2A6
10) Confidence 0.23 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773754 Disease Relevance 0.62 Pain Relevance 0
Diethyldithiocarbamate is also known to be a specific inhibitor of CYP2A6 [18], and the present study confirmed the potent inhibitory capability of this compound on CYP2A6-mediated metabolism.


Negative_regulation (inhibitor) of CYP2A6
11) Confidence 0.12 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664607 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox